• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Feasibility and safety of cangrelor in patients with suboptimal P2Y inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry.

作者信息

Selvarajah Abi, Tavenier Annerieke H, Bor Wilbert L, Houben Vital, Rasoul Saman, Kaplan Eliza, Teeuwen Koen, Hofma Sjoerd H, Lipsic Erik, Amoroso Giovanni, van Leeuwen Maarten A H, Ten Berg Jur M, van 't Hof Arnoud W J, Hermanides Renicus S

机构信息

Department of Cardiology, Isala Hospital, Zwolle, The Netherlands.

Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.

出版信息

Eur Heart J Open. 2021 Oct 18;1(3):oeab028. doi: 10.1093/ehjopen/oeab028. eCollection 2021 Nov.

DOI:10.1093/ehjopen/oeab028
PMID:35923807
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9242080/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c3a/9242080/cac49c293ddd/oeab028f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c3a/9242080/cac49c293ddd/oeab028f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c3a/9242080/cac49c293ddd/oeab028f1.jpg

相似文献

1
Feasibility and safety of cangrelor in patients with suboptimal P2Y inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry.坎格雷洛在经皮冠状动脉介入治疗时P2Y抑制效果欠佳患者中的可行性与安全性：荷兰坎格雷洛注册研究
Eur Heart J Open. 2021 Oct 18;1(3):oeab028. doi: 10.1093/ehjopen/oeab028. eCollection 2021 Nov.
2
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.在接受直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者中，用坎格瑞洛和替卡格雷洛进行血小板抑制。
Circulation. 2019 Apr 2;139(14):1661-1670. doi: 10.1161/CIRCULATIONAHA.118.038317.
3
A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.经皮冠状动脉介入治疗患者中坎格雷洛、普拉格雷、替格瑞洛和氯吡格雷的比较：一项网状Meta分析。
Cardiovasc Revasc Med. 2017 Mar;18(2):79-85. doi: 10.1016/j.carrev.2016.10.005. Epub 2016 Oct 21.
4
Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.坎格雷洛静脉内抑制P2Y12受体对急性冠状动脉综合征和心源性休克患者的影响——病例系列
Cell Physiol Biochem. 2017;42(4):1336-1341. doi: 10.1159/000478962. Epub 2017 Jul 13.
5
Cangrelor Use Patterns and Transition to Oral P2Y Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry.替格瑞洛在心肌梗死患者中的使用模式及向口服 P2Y12 抑制剂的转换：CAMEO 登记研究的初步结果。
J Am Heart Assoc. 2022 Jun 7;11(11):e024513. doi: 10.1161/JAHA.121.024513. Epub 2022 May 27.
6
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.静脉注射P2Y12血小板受体拮抗剂用于经皮冠状动脉介入治疗患者的初步经验：一项分为两部分的II期多中心随机安慰剂对照和活性药物对照试验的结果
Am Heart J. 2006 Mar;151(3):689.e1-689.e10. doi: 10.1016/j.ahj.2005.11.014.
7
Periprocedural platelet inhibition with cangrelor in P2Y-inhibitor naïve patients with acute coronary syndromes - A matched-control pharmacodynamic comparison in real-world patients.在未使用P2Y抑制剂的急性冠状动脉综合征患者中使用坎格雷洛进行围手术期血小板抑制——真实世界患者的配对对照药效学比较
Int J Cardiol. 2016 Nov 15;223:848-851. doi: 10.1016/j.ijcard.2016.08.270. Epub 2016 Aug 17.
8
Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.在现实世界中患有ST段抬高型心肌梗死的患者进行直接经皮冠状动脉介入治疗期间及之后，坎格雷洛与替格瑞洛联合使用可提供持续且强效的P2Y12抑制作用。
Platelets. 2017 Jun;28(4):414-416. doi: 10.1080/09537104.2016.1246714. Epub 2016 Nov 25.
9
Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial. Cangrelor 与替格瑞洛在接受直接经皮冠状动脉介入治疗的患者中的应用：对血小板活性、心肌微血管功能和梗死面积的影响：一项随机对照试验。
Thromb Haemost. 2019 Jul;119(7):1171-1181. doi: 10.1055/s-0039-1688789. Epub 2019 May 26.
10
Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention.Meta 分析坎格雷洛在经皮冠状动脉介入治疗患者中的作用。
Am J Cardiol. 2019 Apr 1;123(7):1069-1075. doi: 10.1016/j.amjcard.2018.12.039. Epub 2019 Jan 5.

引用本文的文献

1
Pharmacodynamic effects of cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII Registry.坎格雷洛在接受经皮冠状动脉介入治疗的急性或慢性冠状动脉综合征患者中的药效学效应：庞贝城登记研究
EuroIntervention. 2025 May 16;21(10):560-570. doi: 10.4244/EIJ-D-24-00757.
2
Antiplatelet strategy during ad-hoc percutaneous coronary intervention in elective patients: how aggressive should we be?择期患者临时经皮冠状动脉介入治疗期间的抗血小板策略：我们应采取多积极的措施？
Neth Heart J. 2023 Nov;31(11):424-425. doi: 10.1007/s12471-023-01825-9. Epub 2023 Oct 20.
3
Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome.

本文引用的文献

1
Feasibility and safety of cangrelor in patients with suboptimal P2Y inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry.在接受经皮冠状动脉介入治疗的 P2Y 抑制作用不理想的患者中使用坎格雷洛的可行性和安全性：荷兰坎格雷洛注册研究的原理。
BMC Cardiovasc Disord. 2021 Jun 12;21(1):292. doi: 10.1186/s12872-021-02093-4.
2
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).2017年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的冠状动脉疾病双联抗血小板治疗重点更新：欧洲心脏病学会（ESC）和欧洲心胸外科学会（EACTS）冠状动脉疾病双联抗血小板治疗特别工作组。
Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419.
3
优化抗栓治疗以减轻急性冠状动脉综合征患者心血管缺血事件负担的当前及未来见解
J Clin Med. 2022 Sep 23;11(19):5605. doi: 10.3390/jcm11195605.
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.坎格雷洛对经皮冠状动脉介入治疗围术期结局的影响：患者水平数据的汇总分析。
Lancet. 2013 Dec 14;382(9909):1981-92. doi: 10.1016/S0140-6736(13)61615-3. Epub 2013 Sep 3.
4
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.随机评估替格瑞洛与普拉格雷在 ST 段抬高型心肌梗死患者中的抗血小板作用。
Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20.